Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139910 | 1.00 | CHRNB1 (0.33) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL2138226 | 0.90 | CYP11B2 (0.39) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL2140764 | 0.90 | CTSA (0.34) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL2140756 | 0.90 | CTSA (0.34) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL2138169 | 0.90 | CYP11B2 (0.39) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3398727 | 0.88 | ABL1 (0.34) | CTSA | |
| SCHEMBL316221 | 0.88 | ABL1 (0.34) | CTSA | |
| SCHEMBL2141249 | 0.86 | XDH (0.38) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL2141252 | 0.86 | XDH (0.38) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL315640 | 0.84 | PIK3CG (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148407-B2 | Compounds derived from 5-thioxylose and their use in therapeutics | LABORATORIES FOURNIER S.A. (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | INVENTIVA (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1861411-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100413-A9 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | FOURNIER LAB SA (FR) | 2007-10-18 | — | — | WO | disclosed |
| WO-2006100413-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | TPMT, STS, TBXAS1 | CHRNB1 4192/4885CHRNB2 4818/4885CHRNB4 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.